Literature DB >> 32449629

The Survival Benefit of Combination Therapy With Mild Temperature Hyperthermia and an Herbal Prescription of Gun-Chil-Jung in 54 Cancer Patients Treated With Chemotherapy or Radiation Therapy: A Retrospective Study.

Hyeong Joon Jun1, So-Jung Park2, Hwi-Joong Kang1, Ga-Young Lee3, Namhun Lee3, Ji Hye Park1, Hwa-Seung Yoo1.   

Abstract

Background: The combination of herbal medicine with conventional treatment increases the survival rate of cancer patients, but the effect is not great. Hyperthermia may have a synergistic effect with herbal medicine alongside conventional medicine. Objective: To monitor the efficacy of hyperthermia together with Gun-Chil-Jung (GCJ) capsule for event-free survival (EFS) and overall survival (OS) for the treatment of various cancers.
Methods: We collected data retrospectively on 54 cancer patients of all stages. They were divided into 4 groups according to each hyperthermia or GCJ treatment period. Hyperthermia with 0.46 MHz radiofrequency wave was applied a power of 50 to 100 W for 70 minutes. GCJ capsules were administered orally 3 times a day.
Results: The median follow-up was 13.4 months, and 25 (55.6%) patients showed disease-related events. Hyperthermia with GCJ treatment was administered in combination group (n = 36, 66.7%) and traditional Korean medicine-only group (n = 17, 31.5%). The median EFS was 190 days, and the median OS was 390 days. The group of hyperthermia 7 times or fewer and GCJ more than 28 days showed longer EFS and OS. The analysis of superiority between hyperthermia and GCJ showed no significant difference (EFS, P = .55; OS, P = .364). Conclusions: The combination of hyperthermia 1 to 2 times a week with GCJ treatment may improve survival of cancer patients treated or being treated with conventional cancer therapies.

Entities:  

Keywords:  Gun-Chil-Jung; combination therapy; event-free survival; hyperthermia; overall survival

Year:  2020        PMID: 32449629     DOI: 10.1177/1534735420926583

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


  2 in total

Review 1.  Systematic review about complementary medical hyperthermia in oncology.

Authors:  Christina Maria Liebl; Sabine Kutschan; Jennifer Dörfler; Lukas Käsmann; Jutta Hübner
Journal:  Clin Exp Med       Date:  2022-06-29       Impact factor: 5.057

2.  Hsp90 Inhibitor STA9090 Sensitizes Hepatocellular Carcinoma to Hyperthermia-Induced DNA Damage by Suppressing DNA-PKcs Protein Stability and mRNA Transcription.

Authors:  Lixia Liu; Yaotang Deng; Zhenming Zheng; Zihao Deng; Jinxin Zhang; Jieyou Li; Manfeng Liang; Xueqiong Zhou; Wenchong Tan; Hongjun Yang; Leonard M Neckers; Fei Zou; Xuemei Chen
Journal:  Mol Cancer Ther       Date:  2021-08-10       Impact factor: 6.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.